Sympathetic overactivity in patients with chronic renal failure - The culprit of increased cardiovascular mortality?

Current Hypertension Reviews

Volumn 2, Issue 4, 2006, Pages 297-300

  Hausberg, Martin ^a   Hillebrandt, Uta ^a   Lang, Detlef ^a   Levers, Andrea ^a   Kosch, Markus ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chronic renal failure; Kidney transplantation; Large artery structure and function; Renin angiotensin aldosteron system; Sympathetic nerve activity

Indexed keywords

ADENOSINE; ADRENERGIC RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLINE DERIVATIVE; MOXONIDINE;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ARTERY WALL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHEMORECEPTOR; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; EFFERENT NERVE; GRAFT VERSUS HOST REACTION; HEART DISEASE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; MECHANORECEPTOR; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SENSORY NERVE; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE; SYMPATHETIC TONE;

EID: 33750705606     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340206778742502     Document Type: Review

References (30)

1. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-82.
2. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11: 723-8.
3. Hausberg M, Kosch M, Harmelink P, el al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-9.
4. Recordati G, Moss NG, Genovesi S, Rogenes P. Renal chemoreceptors. J Auton Nerv Syst 1981; 3: 237-51.
5. Recordati G, Zorzoli F, Pontara O, Turolo L, Zanchetti A. Factors influencing acute ischaemia-induced renal hypertension in rats. J Hypertens 2002; 20: 2453-63.
6. Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997; 99: 540-8.
7. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004; 15: 435-41.
8. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-33.
9. Converse RL Jr., Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-8.
10. Curtis JJ, Luke RG, Diethelm AG, Whelchel JD, Jones P. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985; 2(8458): 739-42.
11. Midtvedt K, Hartmann A, Bentdal O, Brekke IB, Fauchald P. Bilateral nephrectomy simultaneously with renal allografting does not alleviate hypertension 3 months following living-donor transplantation. Nephrol Dial Transplant 1996; 11: 2045-9.
12. Teixeira MC, Nahas WC, Mazucchi E, Ianhez LE, David-Neto E. Role of the peripheral renin profile in predicting blood pressure control after bilateral nephrectomy in renal-transplanted patients. Nephrol Dial Transplant 1998; 13: 2092-7.
13. Hausberg M, Barenbrock M, Kosch M, Kisters K, Suwelack B, Rahn KH. Hypertension after kidney transplantation. Rev Bras Hipertens 2002; 9: 125-33.
14. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003; 108: 560-5.
15. Failla M, Grappiolo A, Emanuelli G, et al. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens 1999; 17: 1117-23.
16. Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship between muscle sympathetic nerve activity and large artery mechanical vessel wall properties in renal transplant patients. J Hypertens 2002; 20: 501-8.
17. Barenbrock M, Kosch M, Joster E, Kisters K, Rahn KH, Hausberg M. Reduced arterial distensibility is a predictor of cardiovascular disease in patients after renal transplantation. J Hypertens 2002; 20: 79-84.
18. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-9.
19. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995; 26: 861-5.
20. Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11: 1469-78.
21. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-9.
22. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8.
23. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425-30.
24. Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33: 862-8.
25. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-31.
26. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004; 15: 2902-7.
27. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21: 1709-17.
28. Hausberg M, Kosch M, Suwelack B, et al. Sympathetic nerve activity and blood pressure in renal transplant recipients before and after withdrawal of calcineurin inhibitors. J.Hypertens 2002; 20 suppl. 4: S91.
29. Wanner C, Krane V, Marz W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004; 27: 259-66.
30. Jardine AG, Holdaas H, Fellstrom B, et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004; 4: 988-95.